Should EDTA chelation therapy be used instead of long-term clopidogrel plus aspirin to treat patients at risk from drug-eluting stents?

Alternative Medicine Review

Volumn 12, Issue 2, 2007, Pages 152-158

  Chappell, L Terry ^a,b,c,d,e  

^a International College of Integrative Medicine ^*  (United States)

^b American Board of Clinical Metal Toxicology   (United States)

^c American Board of Clinical Metal Toxicology   (United States)

^d NIH funded Trial to Assess Chelation Therapy   (United States)

^e NIH funded Trial to Assess Chelation Therapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EDETIC ACID; RAPAMYCIN;

BLEEDING; BLOOD CLOT; CHELATION THERAPY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; DRUG MECHANISM; HEART INFARCTION; HUMAN; RESTENOSIS; REVIEW; SUDDEN DEATH; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CHELATING AGENTS; DRUG IMPLANTS; EDETIC ACID; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; STENTS; TICLOPIDINE;

EID: 34547494625     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Lagerqvist B, James SK, Stenestrand U, et.al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
2. http://www.fda.gov/cdrh/news/091406.html [Accessed May 14, 2007]
3. http://www.fda.gov/cdrh/news/010407.html [Accessed May 14, 2007]
4. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006;355:2395-2407.
5. No authors listed. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-1339.
6. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
7. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168.
8. Chappell LT, Stahl JP. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 1993;6:139-163.
9. Olmstead SF. A Critical Review of EDTA Chelation Therapy in the Treatment of Occlusive Vascular Disease. Klamath Falls, OR: Merle West Medical Center Foundaton; 1998.
10. Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA 2002;287:481-486.
11. Kindness G, Frackelton JP. Effect of ethylene diamine tetraacetic acid (EDTA) on platelet aggregation in human blood. J Adv Med 1989:2:519-530.
12. Zucker MB, Grant RA. Nonreversible loss of platelet aggregability induced by calcium deprivation. Blood 1978;52:505-513.
13. Menke A, Muntner P, Batuman V, et al. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation 2006;114:1388-1394.
14. Cranton EM. A Textbook on EDTA Chelation Therapy. 2nd ed. Charlottesville, VA: Hampton Roads Publishing Company; 2001.
15. Chappell LT, Shukla R, Yang J, et al. Subsequent cardiac and stroke events in patients with known vascular disease treated with EDTA chelation therapy. Evid Based Integr Med 2005;2:27-35.
16. Chiuve SE, McCullough ML, Sacks FM, et al. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation 2006;114:160-167.
17. Farb A, Boam AB. Stent thrombosis redux - the FDA perspective. N Engl J Med 2007;356:984-987.